About the EPISEEK Multi-Cancer Early Detection Test

Early detection can be the difference between life and death when it comes to cancer. Now you can take control of your health with EPISEEK, a groundbreaking multi-cancer early detection (MCED) test that screens for over 60 types of cancer with a simple blood draw. This innovative liquid biopsy test detects hypermethylated DNA loci—areas commonly hypermethylated across various cancers—enabling early, accurate detection, even before symptoms appear.

Using advanced epigenomic analysis technology, EPISEEK is cost-effective, precise, and minimally invasive. It may detect cancer earlier than traditional imaging methods and is more accessible than a tissue biopsy. Order your test kit, have your blood drawn at a convenient location, and receive your secure electronic results to review with your healthcare provider.

Learn More

Included

• 1 (ONE) EPISEEK multi-cancer early detection blood test kit with lab processing

Tests For

DNA changes associated with over 60 types of cancer including brain, lung, breast, colon, prostate, bladder, kidney, pancreas, uterine, cervical, ovarian, lymphoma, leukemia, myeloma, thyroid, oral, liver, esophagus, skin, and many more

Why Screen for Multiple Cancers Early

The 5-year survival rate for cancer detected early is 64%*, compared to much lower rates for late-stage detection. Many aggressive cancers—such as bladder, esophagus, liver, pancreas, and ovarian cancers—do not have widely adopted screening methods. EPISEEK fills this critical gap by screening for these hard-to-detect cancers alongside more common types, all with a single blood test.

EPISEEK is recommended for adults with an elevated risk for cancer, particularly those aged 45 or older. Early detection means more treatment options, better outcomes, and peace of mind.

*The American Cancer Society

How Accurate is the EPISEEK Test?

EPISEEK uses a specificity of 99%, meaning it accurately identifies those without cancer 99% of the time.

In patients 50 years and older:

• Positive predictive value (PPV): 40%

• Negative predictive value (NPV): 99%

For aggressive stages I and II cancers that do not have widely adopted screening—such as bladder, esophagus, liver, head and neck SCC, lung, pancreas, stomach, and uterine—EPISEEK has a sensitivity of 57%.

For stage III cancer, which is still operable in many cases, the sensitivity is 73%.

How Does the EPISEEK Test Work?

• EPISEEK is a liquid biopsy test that analyzes your blood for epigenomic modifications—specific DNA methylation patterns that indicate the presence of cancer.

• By detecting these changes, EPISEEK can identify cancer signals before symptoms develop or before cancer is visible on imaging scans.

• After ordering your test kit, you’ll receive instructions for a simple blood draw at a convenient location.

• Your sample is then sent to the lab for analysis using advanced technology software.

• Results are typically available within 2–3 weeks and should be reviewed with your healthcare provider.

What Happens if My Test Shows an Abnormal Signal?

A test result of “Abnormal Methylation Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (such as imaging) to confirm or exclude the presence of cancer. Your healthcare provider will guide you through the appropriate next steps based on your results and medical history.

If cancer is not confirmed with further testing, it could mean that cancer is not present or that confirmatory testing was insufficient to detect a very early cancer. Follow-up testing may be recommended.

Important Information About EPISEEK

• The EPISEEK test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider.

• EPISEEK is intended to detect cancer signals.

• Use of EPISEEK is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

• Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms.

• A test result of “Cancer Signal Not Detected” does not completely rule out cancer.

• False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur.